SEC Form 4 · accession 0001144204-17-021380
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natasha Giordano
Officer — President and CEO · Director
Period of report
Apr 19, 2017
Accepted (ET)
Apr 20, 2017 · 9:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 19, 2017 | A | 1,086 | — | A | 1,086 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF2,F3 | $12.44 | Apr 19, 2017 | A | 216,580 | A | — | Sep 25, 2025 | Common Stock | 216,580 | 216,580 | D |
Explanation of responses
- F1Received in exchange for 1,380 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
- F2Received in connection with the Merger in exchange for an employee stock option to buy 275,000 shares of PLx Opco Inc. common stock for $9.80 per share.
- F3The option is exercisable as to 108,290 shares as of the date hereof, and will become exercisable as to an additional 54,145 shares on each of January 1, 2018 and (subject to continued employment through such date) January 1, 2019.